PER percheron therapeutics limited

Ann: Webinar Presentation - Phase IIb study of avicursen, page-8

  1. 115 Posts.
    lightbulb Created with Sketch. 16
    So from my take on the Webinar the Company is dropping ATL 1102 , but over time we have been advised repeatedly about how the drug has good anti- inflammatory properties that could be applicable in numerous diseases and a potential huge market. It would appear from listening today that Company has decided it will not be continuing down that path for the drug. Was the whole anti-inflammatory story just more spin from the BOD to keep us shareholders hanging in.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.9¢
Change
0.000(0.00%)
Mkt cap ! $9.786M
Open High Low Value Volume
0.9¢ 0.9¢ 0.9¢ $1.62K 180K

Buyers (Bids)

No. Vol. Price($)
4 364826 0.9¢
 

Sellers (Offers)

Price($) Vol. No.
1.0¢ 8026021 8
View Market Depth
Last trade - 10.37am 25/07/2025 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.